Welcome to Crene Biotechnology!


Product :


Atezolizumab 1380723-44-3
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:Atezolizumab Purity:95% min
CAS NO:1380723-44-3 Solubility:Soluble in DMSO
Molecular Formula:C6446H9902N1706O1998S42 Package:Package according to customer requirements
Molecular Weight:144,612.59 g/mol Storage:Store at -20℃
Quality control

Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer.Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."

For some cancers (notably bladder) the probability of benefit is related to PD-L1 expression, but most cancers with PD-L1 expression still do not respond, and many (about 15%) without PD-L1 expression do respond.



Related Prodcuts: 

Pembrolimumab; Secukinumab; Infliximab; Ramucirumab; Ipilimumab; Daratumumab; Dulaglutide; Rituximab; Adalimumab; Denosumab; Cetuximab; Bevacizumab 

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China